Targeting PCSK9 to upregulate MHC-II on the surface of tumor cells in tumor immunotherapy

Targeting PCSK9 to upregulate MHC-II on the surface of tumor cells in tumor immunotherapy

Abstract Background Proprotein convertase subtilisin/kexin type 9 (PCSK9), the last member of the proprotein convertase family, functions as a classic regulator of low-density lipoprotein (LDL) by interacting with low-density lipoprotein receptor (LDLR). Recent studies have shown that PCSK9 can affe...

Full description

Bibliographic Details
Main Authors: Hanbing Wang, Xin Zhang, Yipeng Zhang, Tao Shi, Yue Zhang, Xueru Song, Baorui Liu, Yue Wang, Jia Wei
Format: Article
Language:English
Published: BMC 2024-04-01
Series:BMC Cancer
Subjects:
PCSK9
Bioinformatics analysis
Tumor immune microenvironment
Dendritic cells
Major histocompatibility complex-II
Online Access:https://doi.org/10.1186/s12885-024-12148-2

Internet

https://doi.org/10.1186/s12885-024-12148-2

Similar Items